InvestorsHub Logo
Followers 32
Posts 477
Boards Moderated 0
Alias Born 01/08/2008

Re: None

Monday, 08/07/2023 3:49:37 PM

Monday, August 07, 2023 3:49:37 PM

Post# of 7824
1st Quarter US Aesthetic Tox sales for Abbvie, EOLS and Revance past 2 years
  • Abbvie US Botox sales for 1st Q were $409M down 0.7% YOY from $413M in 1st Q 2022 (-$4M)
  • EOLS Jeauveau Sales for 1st Q 2023 were $41 M up 23% YOY from $33.9 in 1st Q 2022 (+7M)
  • Revance Daxxify sales for 1st Q 2023 were $15.4M up from Zero in 1st q 2022

2nd Quarter US Aesthetic Tox sales for Abbvie, EOLS and Revance past 2 years
  • Abbvie US Botox sales for 2nd Q were $420M down 7% YOY from $449M in 2nd Q 2022 (-$29M)
  • EOLS Jeauveau Sales for 2nd Q were $49.3M up 33% YOY from $37.2 in 2nd Q 2022 (+12M)
  • Revance Daxxify for 2nd Q will be known tomorrow at 2nd Q release.

Does anyone have any analyst estimates on Daxxify sales for 2nd q 2023?

"People are best convinced by reasons they discover themselves"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News